FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891737771> ?p ?o ?g. }

• W2891737771 endingPage "232" @default.
• W2891737771 startingPage "1" @default.
• W2891737771 abstract "Background Standing frames are recommended as part of postural management for young people with cerebral palsy (CP) Gross Motor Function Classification System (GMFCS) level IV or V. They may have a variety of benefits, including improving bone mineral density, gastrointestinal function and social participation. The NHS needs to know if these benefits are real, given the cost implications of use and the reported negative effects (e.g. pain). The lack of evidence for the clinical effectiveness of standing frames demonstrates the need for evaluative research. Objective(s) The aim of the study was to explore the acceptability of a future trial to determine the clinical effectiveness of standing frames. Design A sequential mixed-methods design was used. The findings of each stage informed the next stage. We conducted surveys, focus groups and in-depth interviews. Participants Professionals who work with young people who use standing frames and parents who have a child who uses a standing frame took part in a survey of current standing frame practice ( n = 551), a series of focus groups (seven focus groups, 49 participants in total) and a survey of research trial acceptability and feasibility ( n = 585). Twelve young people who use a standing frame were interviewed. Results Standing frames were widely used as part of postural management for young people with CP both in school and at home but more frequently in school, and particularly by young people in primary school. Achieving the prescribed use was not always possible owing to resources, environment and family factors. Participation and activity engagement were important to young people. The majority of participants believed that standing frames research is necessary. Some reported concern that stopping standing frame use for a trial would cause irreversible damage. The maximum amount of time most health professionals and parents would agree to suspend standing frame use would be 12 weeks. Limitations Owing to the nature of recruitment, we could not calculate response rates or determine non-response bias. Therefore, participants may not be representative of all standing frame users. Conclusions Although parents and professionals who engaged in the qualitative aspect of this research and stakeholders who took part in the design workshops appreciated the lack of clinical evidence, our surveys, qualitative information and PPI demonstrated that most people had strong beliefs regarding the clinical effectiveness of standing frames. However, with key stakeholder engagement and careful planning, a trial would be acceptable. Future work We recommend a carefully planned trial that includes a pilot phase. The trial should evaluate the following question: ‘does using a standing frame in school improve patient-reported outcomes of participation (primary outcome), quality of life, subjective well-being, body function and body structure (secondary outcomes) in young children (aged 4–11 years) with CP GMFCS III–V?’. Funding The National Institute for Health Research Health Technology Assessment programme." @default.
• W2891737771 created "2018-09-27" @default.
• W2891737771 creator A5002415902 @default.
• W2891737771 creator A5010897540 @default.
• W2891737771 creator A5016394784 @default.
• W2891737771 creator A5020335882 @default.
• W2891737771 creator A5031778168 @default.
• W2891737771 creator A5053887545 @default.
• W2891737771 creator A5058418549 @default.
• W2891737771 creator A5064362775 @default.
• W2891737771 creator A5064447354 @default.
• W2891737771 creator A5066801957 @default.
• W2891737771 creator A5081487448 @default.
• W2891737771 creator A5082051273 @default.
• W2891737771 creator A5090802801 @default.
• W2891737771 date "2018-09-01" @default.
• W2891737771 modified "2023-10-14" @default.
• W2891737771 title "Standing frames for children with cerebral palsy: a mixed-methods feasibility study" @default.
• W2891737771 cites W1527150320 @default.
• W2891737771 cites W1560006339 @default.
• W2891737771 cites W1968742528 @default.
• W2891737771 cites W1971765404 @default.
• W2891737771 cites W1976158951 @default.
• W2891737771 cites W1976770755 @default.
• W2891737771 cites W1979538557 @default.
• W2891737771 cites W1994929408 @default.
• W2891737771 cites W2009474453 @default.
• W2891737771 cites W2010802962 @default.
• W2891737771 cites W2022167001 @default.
• W2891737771 cites W2024905347 @default.
• W2891737771 cites W2048632922 @default.
• W2891737771 cites W2052238918 @default.
• W2891737771 cites W2081659499 @default.
• W2891737771 cites W2081878737 @default.
• W2891737771 cites W2104667268 @default.
• W2891737771 cites W2105605524 @default.
• W2891737771 cites W2110224036 @default.
• W2891737771 cites W2110299605 @default.
• W2891737771 cites W2119400573 @default.
• W2891737771 cites W2122345197 @default.
• W2891737771 cites W2123009097 @default.
• W2891737771 cites W2130836094 @default.
• W2891737771 cites W2149900006 @default.
• W2891737771 cites W2171991128 @default.
• W2891737771 cites W2329968787 @default.
• W2891737771 cites W2429180991 @default.
• W2891737771 cites W4248854933 @default.
• W2891737771 doi "https://doi.org/10.3310/hta22500" @default.
• W2891737771 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6174326" @default.
• W2891737771 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30234480" @default.
• W2891737771 hasPublicationYear "2018" @default.
• W2891737771 type Work @default.
• W2891737771 sameAs 2891737771 @default.
• W2891737771 citedByCount "8" @default.
• W2891737771 countsByYear W28917377712020 @default.
• W2891737771 countsByYear W28917377712021 @default.
• W2891737771 countsByYear W28917377712022 @default.
• W2891737771 countsByYear W28917377712023 @default.
• W2891737771 crossrefType "journal-article" @default.
• W2891737771 hasAuthorship W2891737771A5002415902 @default.
• W2891737771 hasAuthorship W2891737771A5010897540 @default.
• W2891737771 hasAuthorship W2891737771A5016394784 @default.
• W2891737771 hasAuthorship W2891737771A5020335882 @default.
• W2891737771 hasAuthorship W2891737771A5031778168 @default.
• W2891737771 hasAuthorship W2891737771A5053887545 @default.
• W2891737771 hasAuthorship W2891737771A5058418549 @default.
• W2891737771 hasAuthorship W2891737771A5064362775 @default.
• W2891737771 hasAuthorship W2891737771A5064447354 @default.
• W2891737771 hasAuthorship W2891737771A5066801957 @default.
• W2891737771 hasAuthorship W2891737771A5081487448 @default.
• W2891737771 hasAuthorship W2891737771A5082051273 @default.
• W2891737771 hasAuthorship W2891737771A5090802801 @default.
• W2891737771 hasBestOaLocation W28917377711 @default.
• W2891737771 hasConcept C144133560 @default.
• W2891737771 hasConcept C15744967 @default.
• W2891737771 hasConcept C162853370 @default.
• W2891737771 hasConcept C1862650 @default.
• W2891737771 hasConcept C2776659555 @default.
• W2891737771 hasConcept C2779421357 @default.
• W2891737771 hasConcept C56995899 @default.
• W2891737771 hasConcept C71924100 @default.
• W2891737771 hasConcept C99508421 @default.
• W2891737771 hasConceptScore W2891737771C144133560 @default.
• W2891737771 hasConceptScore W2891737771C15744967 @default.
• W2891737771 hasConceptScore W2891737771C162853370 @default.
• W2891737771 hasConceptScore W2891737771C1862650 @default.
• W2891737771 hasConceptScore W2891737771C2776659555 @default.
• W2891737771 hasConceptScore W2891737771C2779421357 @default.
• W2891737771 hasConceptScore W2891737771C56995899 @default.
• W2891737771 hasConceptScore W2891737771C71924100 @default.
• W2891737771 hasConceptScore W2891737771C99508421 @default.
• W2891737771 hasFunder F4320334661 @default.
• W2891737771 hasIssue "50" @default.
• W2891737771 hasLocation W28917377711 @default.
• W2891737771 hasLocation W28917377712 @default.
• W2891737771 hasLocation W28917377713 @default.
• W2891737771 hasLocation W28917377714 @default.
• W2891737771 hasOpenAccess W2891737771 @default.

• next